Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
James W. Green, insider at Harvard Bioscience

James W. Green Insider Information

James Green is Chairman, President and Chief Executive Officer of Harvard Bioscience. He was named President and Chief Executive Officer in July 2019 and Chairman of the Board of Directors in June 2017. Green has been a member of the Company’s Board of Directors since April 2015. Green served as President and Chief Executive Officer of Analogic Corporation (NASDAQ: ALOG) from 2007 to 2016. While leading the public company through the great recession, Analogic’s core revenues grew over 50%, and gross margins, operating margins and earnings per share dramatically improved.  Immediately prior to becoming President and Chief Executive Officer of Harvard Bioscience, Green served as President of Spacelabs Healthcare, where he led a successful global restructuring, rationalizing the company’s cost structure and product portfolio and quickly stabilized revenues while significantly improving operating margins. Earlier in his career, Green was Regional Vice President of a division of Quest Diagnostics Corporation, Sr. VP & General Manager of Koninklijke Philips Electronics NV Global Computed Tomography Business and held various leadership positions at St. Jude Medical Inc., Beckman Instruments, McDonnell Douglas Corporation and Northrop Advanced Systems. Green earned a bachelor’s degree in electrical engineering from the University of Missouri at Columbia and a master’s degree in computer engineering from the University of Southern California and is a graduate of the Stanford University Executive Program.

What is James W. Green's net worth?

The estimated net worth of James W. Green is at least $8.54 million as of May 9th, 2022. Mr. Green owns 2,319,955 shares of Harvard Bioscience stock worth more than $8,537,434 as of May 22nd. This net worth evaluation does not reflect any other investments that Mr. Green may own. Additionally, Mr. Green receives a salary of $1,020,000.00 as CEO at Harvard Bioscience. Learn More about James W. Green's net worth.

How old is James W. Green?

Mr. Green is currently 64 years old. There are 2 older executives and no younger executives at Harvard Bioscience. Learn More on James W. Green's age.

What is James W. Green's salary?

As the CEO of Harvard Bioscience, Inc., Mr. Green earned a total compensation package of $2,620,453.00 in 2020. Mr. Green earned a salary of $573,710.00, a bonus of $215,304.00, stock awards of $1,223,771.00, options awards of $573,710.00, and other compensation of $33,958.00. Learn More on James W. Green's salary.

How do I contact James W. Green?

The corporate mailing address for Mr. Green and other Harvard Bioscience executives is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. Harvard Bioscience can also be reached via phone at (508) 893-8999 and via email at [email protected] Learn More on James W. Green's contact information.

Has James W. Green been buying or selling shares of Harvard Bioscience?

James W. Green has not been actively trading shares of Harvard Bioscience within the last three months. Learn More on James W. Green's trading history.

Are insiders buying or selling shares of Harvard Bioscience?

During the last twelve months, Harvard Bioscience insiders bought shares 2 times. They purchased a total of 40,000 shares worth more than $147,400.00. The most recent insider tranaction occured on May, 9th when CEO James W Green bought 10,000 shares worth more than $34,000.00. Insiders at Harvard Bioscience own 6.2 % of the company. Learn More about insider trades at Harvard Bioscience.

Information on this page was last updated on 5/9/2022.

James W. Green Insider Trading History at Harvard Bioscience

See Full Table

James W. Green Buying and Selling Activity at Harvard Bioscience

This chart shows James W. Green's buying and selling at Harvard Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harvard Bioscience Company Overview

Harvard Bioscience logo
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Read More

Today's Range

Now: $3.68
Low: $3.58
High: $3.85

50 Day Range

MA: $5.39
Low: $3.43
High: $6.42

2 Week Range

Now: $3.68
Low: $3.36
High: $8.75

Volume

140,427 shs

Average Volume

295,903 shs

Market Capitalization

$151.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.